RetatrutideTriple-Action Metabolic CompoundSafety Rating 7/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Puratek PeptidesBest $/mgCOA ✓ · 3POut of stock | $103.45 | $2.59 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3P | $53.55 | $2.68 | May 19, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3P | $80.95 | $2.70 | May 19, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3P | $58.46 | $2.92 | May 19, 2026 | Buy → |
| Red River PeptidesCOA ✓ · 3P | $29.75 | $2.98 | May 19, 2026 | Buy → |
Overview
About Retatrutide
Mechanism of action
Triple agonist of GLP-1, GIP, and glucagon receptors. Combines appetite suppression, improved insulin sensitivity, and increased energy expenditure.
Safety profile
Nausea, vomiting, diarrhea, reduced appetite, potential cardiovascular effects; still in clinical trials — full profile not established. · Phase II showed strong efficacy/tolerability; GI side effects; novel mechanism; promising safety data
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Retatrutide below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Personal or family history of MTC (by class effect — applies across GLP-1/GIP/Glucagon agonists).
MEN 2 syndrome.
Other GLP-1 agonists (Semaglutide, Tirzepatide) — do not combine.
Related pages
More on Retatrutide
Stack & Compare
Frequently Researched Together
Learn More
Retatrutide Guide
A beginner's guide to Retatrutide — the triple-agonist peptide making headlines in obesity research.
Read full guide · 9 min read →Research
Studies & key findings
- Phase 2 NEJM trial demonstrated up to 24.2% mean body weight reduction at 48 weeks — the highest reported for any investigational anti-obesity agent at the time.
- TRIUMPH-4 Phase 3 topline (Eli Lilly, Dec 2025) reported ~28.7% average body weight reduction at 68 weeks in adults with obesity and knee osteoarthritis; TRANSCEND-T2D-1 topline (Mar 2026) showed ~−2.0% HbA1c and ~16.8% weight reduction in type 2 diabetes.